Results 121 to 130 of about 62,419 (246)
Background Given its narrow therapeutic range, digoxin’s pharmacokinetic parameters in infants are difficult to predict due to variation in birth weight and gestational age, especially for critically ill newborns. There is limited evidence to support the
Shu-Hui Yao +5 more
doaj +1 more source
Digoxin, a cardiac glycoside, functions by inhibiting the sodium potassium ATPase pump. It’s crucial to note that digoxin has a very narrow therapeutic range. Its serum level vary due to changes in body weight, age, renal function, hepatic impairment and
Rajathadri H. Ravikumar +3 more
doaj +1 more source
Digoxin, an Overlooked Agonist of RORγ/RORγT
Digoxin was one of the first identified RORγT receptor inverse agonists inhibiting the differentiation of Th17 cells. However, this compound exhibits inhibitory activity at relatively high concentrations that mediate cytotoxic effects.
Kaja Karaś +7 more
doaj +1 more source
MARPLE: A Proximity‐Triggered CRISPR‐Cas13 Platform for Ultrasensitive Antibody Detection
MARPLE is a modular CRISPR‐Cas13 immunoassay that uses antibody‐induced proximity to trigger a toehold‐exchange reaction, releasing an RNA activator for Cas13. This one‐pot, isothermal architecture enables ultrasensitive (femtomolar) and highly specific detection of diverse antibodies, including therapeutic, pathogen‐specific, and cancer‐associated ...
Elena Spezzani +6 more
wiley +1 more source
Coronary artery grafting in infants [PDF]
Coronary artery bypass grafting (CABG) with cardiac vale repair is an uncommon surgery in infants. CABG is technically demanding in infants due to the small size not only of the coronary arteries but also the potential graft arteries.
Maskari, Salim +3 more
core
Quercetin and Its Nano‐Based Formulations Against Skin Cancer: A Narrative Review
ABSTRACT Background Skin cancer is one of the most prevalent malignancies worldwide, characterized by the abnormal growth of skin cells and significant clinical challenges. Conventional treatments—including surgery, chemotherapy, and radiotherapy—often suffer from limitations such as adverse side effects, tumor resistance, and inadequate efficacy.
Mahtab Khanyabzadeh +14 more
wiley +1 more source
Debra J Tompson,1 Christopher S Crean,2 Mauro Buraglio,1 Thangam Arumugham3 1Clinical Pharmacology Modelling and Simulation, GlaxoSmithKline, Stevenage, Hertfordshire, UK; 2Clinical Pharmacology and Pharmacokinetics, Valeant Pharmaceuticals North America,
Tompson DJ +3 more
doaj
ABSTRACT Background According to global projections, by the year 2050, ischemic heart disease will remain the leading cause of cardiovascular deaths with hypertension as a leading modifiable risk factor for mortality. Improving quality care for patients with acute myocardial infarction (MI) is associated with improved outcomes. Aims There is inadequate
Banaz Sadiq Elias +2 more
wiley +1 more source
Severe Digoxin Toxicity in a Child Managed with Cholestyramine. A Case Report
Digoxin toxicity is a common problem in clinical practice because its therapeutic window is relatively narrow (from 0.5 to 2 ng/ml). The toxic effects occur at concentrations > 2.8 ng/ml and are mainly related to disturbances of cardiac function and ...
Suman Noorani +3 more
doaj +1 more source
Long‐Term Follow‐Up of Patients With Transaldolase Deficiency
ABSTRACT Transaldolase (TALDO) deficiency has a well‐characterized phenotype. However, there are few large cohort studies, and little is known about the long term, including the need for organ transplantation. Our aim was to share a long multicenter experience in managing these patients.
M. Scaglione +18 more
wiley +1 more source

